At Kineticos, our senior team consists of life sciences industry professionals with decades of combined experience and highly-diversified backgrounds. With a wealth of knowledge gained from this extensive life science experience, Kineticos delivers significant value to a range of clients seeking trusted strategy consulting services. Below, you will find information and details about the backgrounds, education, and industry experience of our leadership team members.
Founder and CEO
Mr. Maingi is the Founder and CEO of Kineticos Life Sciences, an award winning life sciences strategy consulting firm. Shailesh has also served on the Board of Directors of a number of biotechs including Locus Biosciences, a CRISPR gene editing start-up and Gallus Biopharmaceuticals. Additionally, Shailesh is Adjunct Faculty at the UNC’s Kenan-Flagler School of Business.
In 2015, Shailesh started a fund to invest in innovative biotechnology companies. Recently, he announced a second investment fund, the Kineticos Disruptor Fund. In 2018, Shailesh co-founded the InVincible Cancer Research Fund, a non profit funding breakthrough science.
Prior to founding Kineticos Life Sciences, Shailesh was a senior executive at Cardinal Health and Sigma-Aldrich. He started his career as an R&D scientist with Roche Diagnostics. Shailesh earned a BS in Chemistry from UNC, Chapel Hill and an MBA from Golden Gate University.
Mr. Maingi’s Areas of Expertise:
- Corporate Strategy and Execution
- Research and Innovation
- Business and Corporate Development
- Process Improvement / Change Management
Mr. Gialenios brings over 30 years of life science, biotech, and pharmaceutical experience to the firm holding numerous R&D and commercial roles over his career.
Most recently, Mr. Gialenios worked for 3 years as an independent consultant taking on interim commercial leadership roles at mid-size biopharma and healthcare companies addressing Commercial Strategy, Operational Alignment and Optimization, and Sales and Marketing Execution. His prior experience includes 27 years across Executive Commercial, Sales and Marketing Leadership, and Scientific roles at Novo Nordisk Pharmaceuticals, Sigma-Aldrich Corp, Charles Rivers Labs, and the United States EPA. As Kinetico’s Chief Commercial Officer, Mr. Gialenios is responsible for the strategic leadership of all business development, marketing , and sales efforts and ensuring the organization’s commercial success.
Mr. Gialenios earned his BS degree in Zoology with a concentration in Medical Sciences from North Carolina State University.
Mr. Gialenios’ Areas of Expertise:
- Corporate Strategy
- Business Development
- Organization/Leadership Structure
- Sales and Marketing
VP, Precision Medicine
Mr. Maingi offers over 8 years of operational and commercial experience to the Kineticos team and runs the Precision Medicine group at Kineticos.
Prior to that, he ran operations for all projects across the firm, managing the day to day operations of each active client engagement, ensuring that high quality outputs are delivered on time and under budget.
Additionally, he co-teaches a class at UNC’s Kenan Flager MBA program and is a board observer for Promaxo, a medical device company building office based modular MRIs
Mr. Maingi’s Areas of Expertise:
- Precision Medicine
- Corporate Strategy
- Primary Market Research
Director of Operations
Mr. Finger is responsible for planning and execution of the projects for Kineticos’ Precision Medicine and Biopharma practices. Mr. Finger brings years of experience on the marketing, business development, strategy, and commercial side of Kineticos to the operational team.
Mr. Finger earned his B.S. in Business Administration with a concentration in Marketing from NC State University.
Mr. Finger’s Areas of Expertise:
- Project Management
- Primary and Secondary Research
- Business Development
- Corporate Strategy
Dr. Tom Zietlow
Dr. Zietlow has nearly 30 years of diverse experience in the pharmaceutical, manufacturing and diagnostics industries, across R&D, product commercialization, brand marketing and management. Tom negotiated and managed joint international ventures in Europe and Asia, including projects and marketing programs in diverse industries for Eastman Kodak, Corpex Technologies, Diagnology, Cardinal Health in the Pharmaceutical Services (PTS) business and Becton Dickinson. Most recently, Tom specialized in the emerging field of personalized medicine, supporting pharmaceutical and diagnostic companies in the commercialization of companion diagnostics as President of Diaceutics.
He received his Ph.D. in chemistry from the California Institute of Technology and an MBA from the Kenan-Flagler School of Business at UNC – Chapel Hill.
Dr. Zietlow’s Areas of Expertise:
- Precision Medicine
- Strategic Planning
Mr. Buckanavage adds over 30 years of commercial experience in the pharmaceutical and biotech industry having successfully launched products in the US, Europe, and Japan. Most recently, Steve held senior commercial positions at Celyad, assisting the Belgium based cell & gene therapy company through a successful US IPO, establishing US operations in Boston, staffing key roles and running operations. Prior to joining Celyad, Mr. Buckanavage was the VP of Commercial Strategy at GSK’s Cancer Immunotherapy Business Unit where he was responsible for the commercial strategy for the antigen specific cancer immunotherapy portfolio. Prior to that, Steve spent over 25 years at AstraZeneca in various roles. He was the US Commercial Head for franchises such as cardiovascular, anesthesia, and infectious disease having launched brands in all three categories. His time at AstraZeneca also included serving as the Global VP of Emerging Oncology responsible for a portfolio of small molecule and biologic assets.
Mr. Buckanavage’s Areas of Expertise:
- Commercial Strategy
- Portfolio Planning
- Corporate Development
Jason Kralic, PhD
Dr. Kralic is a neuropharmacologist and business development executive with broad experience in technology innovation, CNS R&D, licensing, fundraising and company creation. Jason is Co-founder and CEO of Tellus Therapeutics focused on development of treatments for neonatal brain injury, Director of Business Development for Bioscience Pharma Partners focused on development of a treatment of neuroinflammation in neurodegenerative disorders and serves on the scientific advisory board for the Alzheimer’s disease company, T3D Therapeutics. Jason was previously Associate Vice President of Technology Innovation at Wake Forest Baptist Medical Center and Head of Business Development for Neurosciences R&D at GlaxoSmithKline during which he led the divestment of GSK’s Ph3- ready Alzheimer’s disease program, Intepirdine, to Axovant resulting in a $360M IPO (largest of 2016) and helped launch several start-up companies, including Convergence Pharmaceuticals (received $200M upfront from Biogen for license to neuropathic pain programs), PainQx (raised $5M in non-dilutive and equity funding for pain diagnostics platform) and Care Directions (>$300,000 funding for healthcare IT solution for post-stroke management). Jason has also served in business development roles at Opexa Therapeutics, UCB Pharma and Schwarz Biosciences.
Jason holds a Ph.D. in pharmacology from the University of North Carolina at Chapel Hill where he studied novel roles of ion channels in CNS drug response. His post-doctoral training at the University of Zurich focused on the biochemical, pharmacologic and behavioral responses to experimental CNS therapeutics as well as the role of neurogenesis in neurologic disorders.
Dr. Kralic’s Areas of Expertise
- Business Development Strategy and Licensing
- Technical and Commercial Due Diligence
- Drug Development Strategy
Alex Stojanovic, PhD
Dr. Stojanovic brings 15 years of commercial strategy, marketing, and business development experience in the life science industry. Concurrently, he serves as Partner at The Naissos Group, a boutique creative consultancy helping life science companies with multichannel marketing strategy and execution via traditional and digital channels. His background spans consulting and industry roles with more than 50 companies, across 20 countries, with a particular focus in CNS, including fields such as neuropathic pain, neurodegenerative disease, epilepsy, and anesthesia. Prior to joining Kineticos, Dr. Stojanovic served as Vice President of Business Development and Commercial Operations at Phosphagenics, as well as Head of New Products Marketing at Grunenthal, where he was responsible for guiding the commercial development of pipeline entities from phase 1 to phase 3.
Earlier in his career, Dr. Stojanovic spent 6 years with ZS Associates, providing consulting services to biotech and pharmaceutical companies across corporate and commercial strategy.
Dr. Stojanovic’s Areas of Expertise
- Portfolio Optimization
- Commercial Planning
- Drug Delivery
Mr. Montgomery has successfully launched and operationalized real world data-based specialty healthcare businesses to optimally inform market, clinical and financial decision-making for pharmaceutical researchers, providers and payers. Most recently, Mr. Montgomery was Vice President, Analytics for Integra Connect, an emerging healthcare services company focused on expanding care access through high value provider technology and population health analytics in the oncology and urology space. Previously, Mr. Montgomery was Director, Healthcare Analytics for Cardinal Health Specialty Solutions, building and managing Cardinal’s Healthcare Analytics team, including healthcare economics, outcomes research and commercial insights to manufacturers, payers and providers. Mr. Montgomery is an advisory board member of Lantern Pharma and previous board member of the Coalition on Donation (United Network for Organ Sharing).
Mr. Montgomery received a BS in Microbiology from L.S.U. and an MPH from Johns Hopkins Bloomberg School of Public Health.
Mr. Montgomery’s Areas of Expertise:
- Infectious Diseases
- Real World Evidence
- Molecular Diagnostics
Mr. Kopp has 30 years of experience in the global pharmaceutical, biotechnology and healthcare sectors. Michael previous built and ran commercial operations for Mylan’s US hospital business. He subsequently led business development for Mylan’s North American branded and generics businesses, had P&L responsibility for the ex-US EpiPen® franchise, and was accountable for all product selection, portfolio management, alliance management activities. Michael has also held senior leadership roles with Xellia Pharmaceuticals (Novo A/S) Cardinal Health, McKesson, Teva and Sandoz, and previously served on the Board of Directors for DCAT.
His experience spans the pharmaceutical continuum – from API synthesis through patient point of dispensing – and includes nearly all commercial channels and dose forms. Mr. Kopp is a life member of Mensa.
Mr. Kopp’s Areas of Expertise:
- Portfolio Management
- Alliance Management
Mr. Osterman adds more than 25 years of experience in the biopharmaceutical industry to the team.
Mr. Osterman held roles in sales, clinical, and marketing at GlaxoSmithKline before moving to Johnson & Johnson, where he launched their stem cell internal venture and was responsible for the cardiovascular, pulmonary, metabolic, and mimetibody therapeutic areas in the Global Biologic Strategic Marketing. Mr. Osterman then served as Senior Vice President responsible for commercial operations and business development at Discovery Labs before accepting a position as Vice President of Global Marketing at Solstice Neurosciences. Immediately prior to joining Kineticos, he founded the Osterman Strategy Group, a boutique management consulting firm, where he worked with large and emerging biopharmaceutical companies to help solve their most challenging business issues.
Mr. Osterman earned a dual BA in Business Management and Economics from North Carolina State University.
Mr. Osterman’s Areas of Expertise:
- Global Strategic Marketing
- New Business Development
- Merger and Acquisition Strategy
- Organizational and Leadership Development
Mr. Dupere brings 30 years of experience in the biopharmaceutical industry to the Kineticos team. He spent 10 years immersed in formative training across core disciplines including clinical research, regulatory affairs, project, communications, and product management at both medical device (CTL, Inc.) and pharmaceuticals (Burroughs Wellcome Co.). He then started ATOM, Inc., a boutique consultancy focused on helping companies–including Lilly, Genentech, Sanofi and others—project manage the commercial launch their first oncology product. Mr. Dupere progressed to start new business units as Vice President of Business Development at LifeMetrix, retained consultant at US Oncology (Market Focus), and Sr. Vice President, Oncology Biopharmaceutical Solutions at Biologics, Inc. More recently, as COO for QOL Medical, he successfully re-positioned and built out an orphan disease company.
Mr. Dupere earned his BS in Public Health and MBA, both from the University of North Carolina at Chapel Hill.
Mr. Dupere’s Areas of Expertise:
- Product Opportunity Assessment
- Commercialization Strategy
- Out-sourcing Integration
- Patient Access and Optimization